Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.

Williams GP, Schonhoff AM, Jurkuvenaite A, Thome AD, Standaert DG, Harms AS.

J Neuroinflammation. 2018 Aug 30;15(1):244. doi: 10.1186/s12974-018-1286-2.

2.

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.

Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef LW; UAB CBD Program.

Epilepsy Behav. 2018 Aug 9. pii: S1525-5050(18)30473-6. doi: 10.1016/j.yebeh.2018.07.020. [Epub ahead of print]

3.

Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.

Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, Espay AJ.

Mov Disord. 2018 Jul;33(6):928-936. doi: 10.1002/mds.27338. Epub 2018 Mar 23.

PMID:
29570853
4.

Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.

Park HK, Ilango S, Charriez CM, Checkoway H, Riley D, Standaert DG, Bordelon Y, Shprecher DR, Reich SG, Hall D, Kluger B, Marras C, Jankovic J, Dubinsky R, Litvan I; ENGENE-PSP Study.

Mov Disord. 2018 Mar;33(3):468-472. doi: 10.1002/mds.27336. Epub 2018 Feb 20.

PMID:
29460982
5.

Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics.

Standaert DG, Boyd JT, Odin P, Robieson WZ, Zamudio J, Chatamra K.

NPJ Parkinsons Dis. 2018 Jan 24;4:4. doi: 10.1038/s41531-017-0040-2. eCollection 2018.

6.

Anti-inflammatory drug use and progressive supranuclear palsy.

Marras C, Cunningham CR, Hou J, Proudfoot J, Standaert DG, Juncos J, Riley D, Reich SG, Hall D, Kluger B, Bordelon Y, Shprecher DR, Litvan I; for ENGENE-PSP.

Parkinsonism Relat Disord. 2018 Mar;48:89-92. doi: 10.1016/j.parkreldis.2017.11.346. Epub 2017 Dec 6.

PMID:
29307562
7.

Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease.

Standaert DG, Rodriguez RL, Slevin JT, Lobatz M, Eaton S, Chatamra K, Facheris MF, Hall C, Sail K, Jalundhwala YJ, Benesh J.

Mov Disord Clin Pract. 2017 Nov-Dec;4(6):829-837. doi: 10.1002/mdc3.12526. Epub 2017 Sep 20.

8.

Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease.

Harms AS, Thome AD, Yan Z, Schonhoff AM, Williams GP, Li X, Liu Y, Qin H, Benveniste EN, Standaert DG.

Exp Neurol. 2018 Feb;300:179-187. doi: 10.1016/j.expneurol.2017.11.010. Epub 2017 Nov 16.

PMID:
29155051
9.

Genetic influences on cognition in progressive supranuclear palsy.

Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, Shprecher DR, Kluger BM, Litvan I.

Mov Disord. 2017 Dec;32(12):1764-1771. doi: 10.1002/mds.27196. Epub 2017 Oct 27.

PMID:
29076559
10.

What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease.

Standaert DG.

Mov Disord. 2017 Oct;32(10):1341-1342. doi: 10.1002/mds.27206. Review. No abstract available.

PMID:
29068500
11.

Effects of subthalamic nucleus deep brain stimulation on objective sleep outcomes in Parkinson's disease.

Amara AW, Walker HC, Joop A, Cutter G, DeWolfe JL, Harding SM, Standaert DG.

Mov Disord Clin Pract. 2017 Mar-Apr;4(2):183-190. doi: 10.1002/mdc3.12375. Epub 2016 Jun 6.

12.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

13.

Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia.

Zimmerman CN, Eskow Jaunarajs KL, Meringolo M, Rizzo FR, Santoro M, Standaert DG, Pisani A.

Front Syst Neurosci. 2017 Jun 13;11:43. doi: 10.3389/fnsys.2017.00043. eCollection 2017.

14.

Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.

Gendelman HE, Zhang Y, Santamaria P, Olson KE, Schutt CR, Bhatti D, Shetty BLD, Lu Y, Estes KA, Standaert DG, Heinrichs-Graham E, Larson L, Meza JL, Follett M, Forsberg E, Siuzdak G, Wilson TW, Peterson C, Mosley RL.

NPJ Parkinsons Dis. 2017 Mar 23;3:10. doi: 10.1038/s41531-017-0013-5. eCollection 2017.

15.

Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia.

Scarduzio M, Zimmerman CN, Jaunarajs KL, Wang Q, Standaert DG, McMahon LL.

Exp Neurol. 2017 Sep;295:162-175. doi: 10.1016/j.expneurol.2017.06.005. Epub 2017 Jun 3.

16.

Dysregulation of BET proteins in levodopa-induced dyskinesia.

A Figge D, Standaert DG.

Neurobiol Dis. 2017 Jun;102:125-132. doi: 10.1016/j.nbd.2017.03.003. Epub 2017 Mar 9.

17.

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.

Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE.

Mov Disord. 2017 Mar;32(3):319-324. doi: 10.1002/mds.26913. Epub 2017 Feb 24. Review.

18.

The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's disease.

Birchall EL, Walker HC, Cutter G, Guthrie S, Joop A, Memon RA, Watts RL, Standaert DG, Amara AW.

Brain Stimul. 2017 May - Jun;10(3):651-656. doi: 10.1016/j.brs.2016.12.014. Epub 2016 Dec 27.

19.

Understanding falls in progressive supranuclear palsy.

Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J; ENGENE PSP study.

Parkinsonism Relat Disord. 2017 Feb;35:75-81. doi: 10.1016/j.parkreldis.2016.12.009. Epub 2016 Dec 15.

PMID:
28007518
20.

Cholinergic regulation of striatal dopamine release: New light in dark basements.

Zimmerman CN, Standaert DG.

Mov Disord. 2016 Dec;31(12):1796. doi: 10.1002/mds.26846. Epub 2016 Nov 7. No abstract available.

PMID:
27943474
21.

Glucocerebrosidase, Parkinson disease, and the "senses and intellect".

Standaert DG, Geldmacher DS.

Ann Neurol. 2016 Nov;80(5):660-661. doi: 10.1002/ana.24808. No abstract available.

PMID:
27779773
22.

CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial.

Apetauerova D, Scala SA, Hamill RW, Simon DK, Pathak S, Ruthazer R, Standaert DG, Yacoubian TA.

Neurol Neuroimmunol Neuroinflamm. 2016 Aug 2;3(5):e266. doi: 10.1212/NXI.0000000000000266. eCollection 2016 Oct.

23.

SNPing SCNA regulatory elements gives a CRISPR view of genetic susceptibility in Parkinson's disease.

Figge DA, Standaert DG.

Mov Disord. 2016 Oct;31(10):1479. doi: 10.1002/mds.26747. No abstract available.

PMID:
27501414
24.

Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.

Figge DA, Eskow Jaunarajs KL, Standaert DG.

J Neurosci. 2016 Jun 15;36(24):6514-24. doi: 10.1523/JNEUROSCI.0683-16.2016.

25.

Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.

Fraser KB, Rawlins AB, Clark RG, Alcalay RN, Standaert DG, Liu N; Parkinson's Disease Biomarker Program Consortium, West AB.

Mov Disord. 2016 Oct;31(10):1543-1550. doi: 10.1002/mds.26686.

26.

Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis.

Calabresi P, Standaert DG, Chiasserini D, Parnetti L.

Mov Disord. 2016 Jun;31(6):769-70. doi: 10.1002/mds.26683. No abstract available.

PMID:
27245116
27.

Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.

Qin H, Buckley JA, Li X, Liu Y, Fox TH 3rd, Meares GP, Yu H, Yan Z, Harms AS, Li Y, Standaert DG, Benveniste EN.

J Neurosci. 2016 May 4;36(18):5144-59. doi: 10.1523/JNEUROSCI.4658-15.2016.

28.

How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Volpicelli-Daley LA, Kirik D, Stoyka LE, Standaert DG, Harms AS.

J Neurochem. 2016 Oct;139 Suppl 1:131-155. doi: 10.1111/jnc.13627. Epub 2016 May 4. Review.

29.

microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease.

Thome AD, Harms AS, Volpicelli-Daley LA, Standaert DG.

J Neurosci. 2016 Feb 24;36(8):2383-90. doi: 10.1523/JNEUROSCI.3900-15.2016.

30.

The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia.

Ponnazhagan R, Harms AS, Thome AD, Jurkuvenaite A, Gogliotti R, Niswender CM, Conn PJ, Standaert DG.

J Neuroimmune Pharmacol. 2016 Jun;11(2):231-7. doi: 10.1007/s11481-016-9655-z. Epub 2016 Feb 12.

31.

Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.

Litvan I, Lees PS, Cunningham CR, Rai SN, Cambon AC, Standaert DG, Marras C, Juncos J, Riley D, Reich S, Hall D, Kluger B, Bordelon Y, Shprecher DR; for ENGENE-PSP.

Mov Disord. 2016 May;31(5):644-52. doi: 10.1002/mds.26512. Epub 2016 Feb 8.

32.

Invisible Killers.

Volpicelli-Daley LA, Standaert DG.

Mov Disord. 2016 Jan;31(1):44. doi: 10.1002/mds.26465. Epub 2016 Jan 9. No abstract available.

PMID:
26748962
33.

Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.

Thome AD, Standaert DG, Harms AS.

PLoS One. 2015 Oct 15;10(10):e0140566. doi: 10.1371/journal.pone.0140566. eCollection 2015.

34.

Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.

Fernandez HH, Standaert DG, Chatamra K, Benesh JA.

Mov Disord. 2015 Sep;30(10):1435-6. doi: 10.1002/mds.26316. Epub 2015 Jul 16. No abstract available.

35.

Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia.

Eskow Jaunarajs KL, Bonsi P, Chesselet MF, Standaert DG, Pisani A.

Prog Neurobiol. 2015 Apr;127-128:91-107. doi: 10.1016/j.pneurobio.2015.02.002. Epub 2015 Feb 17. Review.

36.

Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Allen Reish HE, Standaert DG.

J Parkinsons Dis. 2015;5(1):1-19. doi: 10.3233/JPD-140491. Review.

37.

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.

Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ.

Mov Disord. 2015 Apr;30(4):500-9. doi: 10.1002/mds.26123. Epub 2014 Dec 24.

38.

Scientific perspectives.

Standaert DG, Olanow CW, Obeso JA.

Mov Disord. 2014 Sep;29(10):1230. doi: 10.1002/mds.26015. No abstract available.

PMID:
25209257
39.

Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.

Lewis TB, Glasgow JN, Harms AS, Standaert DG, Curiel DT.

Viruses. 2014 Aug 21;6(8):3293-310. doi: 10.3390/v6083293.

40.

Monocytes and Parkinson's disease: invaders from outside?

Harms AS, Standaert DG.

Mov Disord. 2014 Sep;29(10):1242. doi: 10.1002/mds.25993. Epub 2014 Aug 14. No abstract available.

PMID:
25124371
41.

A full-brain, bootstrapped analysis of diffusion tensor imaging robustly differentiates Parkinson disease from healthy controls.

Skidmore FM, Spetsieris PG, Anthony T, Cutter GR, von Deneen KM, Liu Y, White KD, Heilman KM, Myers J, Standaert DG, Lahti AC, Eidelberg D, Ulug AM.

Neuroinformatics. 2015 Jan;13(1):7-18. doi: 10.1007/s12021-014-9222-9.

42.

Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.

West AB, Cowell RM, Daher JP, Moehle MS, Hinkle KM, Melrose HL, Standaert DG, Volpicelli-Daley LA.

J Comp Neurol. 2014 Aug 1;522(11):2465-80. doi: 10.1002/cne.23583. Epub 2014 Apr 12.

43.

Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease.

Kelly NA, Ford MP, Standaert DG, Watts RL, Bickel CS, Moellering DR, Tuggle SC, Williams JY, Lieb L, Windham ST, Bamman MM.

J Appl Physiol (1985). 2014 Mar 1;116(5):582-92. doi: 10.1152/japplphysiol.01277.2013. Epub 2014 Jan 9.

44.

Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegeneration.

Yacoubian TA, Standaert DG.

Mov Disord. 2014 Mar;29(3):306. doi: 10.1002/mds.25766. Epub 2014 Jan 2. No abstract available.

PMID:
24395732
45.

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group.

Lancet Neurol. 2014 Feb;13(2):141-9. doi: 10.1016/S1474-4422(13)70293-X. Epub 2013 Dec 20. Erratum in: Lancet Neurol. 2014 Mar;13(3):240.

46.

Metabolomics and the search for biomarkers in Parkinson's disease.

Amara AW, Standaert DG.

Mov Disord. 2013 Oct;28(12):1620-1. doi: 10.1002/mds.25644. Epub 2013 Sep 18. No abstract available.

47.

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.

Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW.

Mov Disord. 2013 Oct;28(12):1675-82. doi: 10.1002/mds.25625. Epub 2013 Sep 3.

48.

LRRK2 secretion in exosomes is regulated by 14-3-3.

Fraser KB, Moehle MS, Daher JP, Webber PJ, Williams JY, Stewart CA, Yacoubian TA, Cowell RM, Dokland T, Ye T, Chen D, Siegal GP, Galemmo RA, Tsika E, Moore DJ, Standaert DG, Kojima K, Mobley JA, West AB.

Hum Mol Genet. 2013 Dec 15;22(24):4988-5000. doi: 10.1093/hmg/ddt346. Epub 2013 Jul 25.

49.

MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration.

Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR, Cron RQ, Shacka JJ, Raman C, Standaert DG.

J Neurosci. 2013 Jun 5;33(23):9592-600. doi: 10.1523/JNEUROSCI.5610-12.2013.

50.

Removing the blinkers: moving beyond striatal dopamine in Parkinson's disease.

Eskow Jaunarajs KL, Standaert DG.

J Neurochem. 2013 Jun;125(5):639-41. doi: 10.1111/jnc.12167. No abstract available.

Supplemental Content

Loading ...
Support Center